Researchers have chosen an experimental drug by Eli Lilly and Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it. The drug, called solanezumab, ( sol anez zu mab ) is designed to bind to and help clear the sticky deposits that clog patients' brains. Earlier studies found it did not help people with moderate to severe Alzheimer's but it showed some promise against milder disease. Researchers think it might work better if given before symptoms start. About 35 million people worldwide have dementia, and Alzheimer's is the most common type.
In the U.S., about 5 million have Alzheimer's.
Current medicines such as Aricept and Namenda just temporarily ease symptoms.
There is no known cure.